🇺🇸 FDA
Patent

US 10086041

Syndecan-4 proteoliposomes for enhanced cutaneous wound healing and minimized inflammatory immune response

granted A61KA61K38/177A61K38/179

Quick answer

US patent 10086041 (Syndecan-4 proteoliposomes for enhanced cutaneous wound healing and minimized inflammatory immune response) held by The Board of Regents of the University of Texas System expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/177, A61K38/179, A61K38/1858, A61K9/0014